Company record · ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. disclosed the departure of Geoffrey Parker as chief financial officer. No successor is on the record yet; see the filing record for the company's words.
The record holds 1 verified CFO change for Allogene Therapeutics, Inc. from Form 8-K filings, filed September 2, 2026 and the CFO signature on its 10-K filed March 12, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Departure disclosed, no successor on the record |
|---|---|
| Basis | Latest move: departure, 8-K filed September 2, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-09-02Departure
Allogene Therapeutics, Inc. discloses CFO departure: Geoffrey Parkereffective November 6, 2026 · 8-K filed September 2, 2026 · sec.gov, Item 5.02
2026-03-1210-K signature
Geoffrey Parker signed the annual report as Chief Financial Officer ( Principal Financial Officer )
10-K filed March 12, 2026 · sec.gov
“/s/ Geoffrey Parker Chief Financial Officer March 12, 2026 Geoffrey Parker ( Principal Financial Officer )”
Company
| Ticker | ALLO |
|---|---|
| SEC CIK | 0001737287 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-30 also names Geoffrey Parker alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-09-02, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
Precision BioSciences, Inc.DTIL
CFO: Naresh Tanna · effective August 1, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.